PMID- 27630309
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20170208
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 9
DP  - 2016 Sep
TI  - Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in 
      Breast Cancer.
PG  - 4661-6
AB  - AIM: We examined an economical method for evaluating the amplification of the 
      human epidermal growth factor receptor 2 (HER2) gene in breast cancer specimens. 
      MATERIALS AND METHODS: We compared HER2 amplification determined by fluorescence 
      in situ hybridization (FISH) on whole-tissue (WT) blocks used for diagnostic and 
      on tissue microarray (TMA) sections for a cohort of 521 consecutive patients with 
      breast cancer. In a subset of 116 patients, we examined HER2 concordance from the 
      WT section and a TMA section from a randomly chosen additional block (a proxy of 
      the core biopsy). RESULTS: Overall concordance for HER2 amplification between WT 
      and TMA sections was 98.2%, and between sections from WT and from the additional 
      block was 99.0%. CONCLUSION: The high concordance rates support the use of TMA 
      for the evaluation of HER2 amplification in breast cancer and suggest that FISH 
      can be used to assess HER2 using core biopsies.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Furrer, Daniela
AU  - Furrer D
AD  - Cancer Research Centre at Laval University, Faculty of Medicine, Laval 
      University, Quebec City, QC, Canada Oncology Axis, CHU of Quebec Research Center, 
      Faculty of Medicine, Laval University, Quebec City, QC, Canada Department of 
      Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec 
      City, QC, Canada.
FAU - Jacob, Simon
AU  - Jacob S
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, QC, Canada Pathology Service, Saint-Sacrement Hospital, Quebec City, QC, 
      Canada Department of Molecular Biology, Medical Biochemistry and Pathology, 
      Faculty of Medicine, Laval University, Quebec City, QC, Canada.
FAU - Caron, Chantal
AU  - Caron C
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, QC, Canada Pathology Service, Saint-Sacrement Hospital, Quebec City, QC, 
      Canada.
FAU - Sanschagrin, Francois
AU  - Sanschagrin F
AD  - Oncology Axis, CHU of Quebec Research Center, Faculty of Medicine, Laval 
      University, Quebec City, QC, Canada Deschenes-Fabia Center for Breast Diseases, 
      Saint-Sacrement Hospital, Quebec City, QC, Canada.
FAU - Provencher, Louise
AU  - Provencher L
AD  - Oncology Axis, CHU of Quebec Research Center, Faculty of Medicine, Laval 
      University, Quebec City, QC, Canada Deschenes-Fabia Center for Breast Diseases, 
      Saint-Sacrement Hospital, Quebec City, QC, Canada Department of Surgery, Faculty 
      of Medicine, Laval University, Quebec City, QC, Canada.
FAU - Diorio, Caroline
AU  - Diorio C
AD  - Cancer Research Centre at Laval University, Faculty of Medicine, Laval 
      University, Quebec City, QC, Canada Oncology Axis, CHU of Quebec Research Center, 
      Faculty of Medicine, Laval University, Quebec City, QC, Canada Department of 
      Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec 
      City, QC, Canada Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement 
      Hospital, Quebec City, QC, Canada caroline.diorio@crchudequebec.ulaval.ca.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biopsy
MH  - Biopsy, Large-Core Needle
MH  - Breast Neoplasms/*metabolism
MH  - Cell Line, Tumor
MH  - Female
MH  - Fibroblasts/metabolism
MH  - Gene Amplification
MH  - Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphocytes/metabolism
MH  - MCF-7 Cells
MH  - Receptor, ErbB-2/*metabolism
MH  - *Tissue Array Analysis
OTO - NOTNLM
OT  - ASCO/CAP guidelines
OT  - Breast cancer
OT  - FISH
OT  - HER2 status
OT  - TMA
OT  - trastuzumab
EDAT- 2016/09/16 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/09/16 06:00
PHST- 2016/07/04 00:00 [received]
PHST- 2016/07/21 00:00 [accepted]
PHST- 2016/09/16 06:00 [entrez]
PHST- 2016/09/16 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - 36/9/4661 [pii]
AID - 10.21873/anticanres.11017 [doi]
PST - ppublish
SO  - Anticancer Res. 2016 Sep;36(9):4661-6. doi: 10.21873/anticanres.11017.